Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival

Abstract

Background: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States. This Annual Report highlights survival rates. Methods: Data were from the CDC- and NCI-funded population-based cancer registry programs and compiled by NAACCR. Trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types by sex were estimated by joinpoint analysis and expressed as annual percent change. We used relative survival ratios and adjusted relative risk of death after a diagnosis of cancer (hazard ratios [HRs]) using Cox regression model to examine changes or differences in survival over time and by sociodemographic factors. Results: Overall cancer death rates from 2010 to 2014 decreased by 1.8% (95% confidence interval [CI] = –1.8 to –1.8) per year in men, by 1.4% (95% CI = –1.4 to –1.3) per year in women, and by 1.6% (95% CI = –2.0 to –1.3) per year in children. Death rates decreased for 11 of the 16 most common cancer types in men and for 13 of the 18 most common cancer types in women, including lung, colorectal, female breast, and prostate, whereas death rates increased for liver (men and women), pancreas (men), brain (men), and uterine cancers. In contrast, overall incidence rates from 2009 to 2013 decreased by 2.3% (95% CI = –3.1 to –1.4) per year in men but stabilized in women. For several but not all cancer types, survival statistically significantly improved over time for both early and late-stage diseases. Between 1975 and 1977, and 2006 and 2012, for example, five-year relative survival for distant-stage disease statistically significantly increased from 18.7% (95% CI = 16.9% to 20.6%) to 33.6% (95% CI = 32.2% to 35.0%) for female breast cancer but not for liver cancer (from 1.1%, 95% CI = 0.3% to 2.9%, to 2.3%, 95% CI = 1.6% to 3.2%). Survival varied by race/ethnicity and state. For example, the adjusted relative risk of death for all cancers combined was 33% (HR = 1.33, 95% CI = 1.32 to 1.34) higher in non-Hispanic blacks and 51% (HR = 1.51, 95% CI = 1.46 to 1.56) higher in non-Hispanic American Indian/Alaska Native compared with non-Hispanic whites. Conclusions: Cancer death rates continue to decrease in the United States. However, progress in reducing death rates and improving survival is limited for several cancer types, underscoring the need for intensified efforts to discover new strategies for prevention, early detection, and treatment and to apply proven preventive measures broadly and equitably.

Predicting Breast Cancer Incidence Rates Among White and Black Women in the United States: An Application of FTS Model

“…To plot this figure, we use rainbow plot [17] for representing different age-groups. The curves are plotted in a rainbow order with the earlier age group (15)(16)(17)(18)(19) is represented by red and the last age-group (85+) is plotted by violet color. The other age groups are appeared in the rainbow order, with Rpackage 'rainbow' is used to construct this plot.…”

Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation

“…In addition to systemic chemotherapy, palliative radiation, and palliative surgery, patients with advanced melanoma may now use immunotherapies, targeted therapies, or combinations of them, either in standard usage or in the clinical trial pipeline. Research on melanoma patients' perspectives is particularly timely as the annual incidence rates for melanoma in the USA have increased significantly and may affect as many as 112,000 new patients per year by 2030 [42,43]. These trends suggest an increased need to understand how melanoma patients make decisions and how these decision-making approaches may relate to patient care and outcomes.…”

Cancer survival in Brazil: Estimate through the mortality to incidence ratio

“…This tumor does not feature differences between the sexes in terms of its etiology. According to data in the study conducted by Jemal et al (2017), the survival rate for colo-rectal cancer on US registers (SEER) was 66.2% in the 2006 to 2012 period.…”